omeprazole has been researched along with Cystic Fibrosis of Pancreas in 16 studies
Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.
5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Omeprazole improves fat digestion and absorption in cystic fibrosis patients with residual faecal fat loss despite maximal pancreatic enzyme substitution." | 9.10 | Omeprazole, a proton pump inhibitor, improves residual steatorrhoea in cystic fibrosis patients treated with high dose pancreatic enzymes. ( De Boeck, K; Proesmans, M, 2003) |
| " In this prospective open study of 14 children with cystic fibrosis (CF), we evaluated the effect of 1 year adjuvant therapy with lansoprazole, a proton pump inhibitor (PPI), on growth, fecal fat loss, body composition and lung function." | 9.09 | Changes in pulmonary hyperinflation and bronchial hyperresponsiveness following treatment with lansoprazole in children with cystic fibrosis. ( Donckerwolcke, R; Forget, PP; Hendriks, JJ; Kester, AD; Wouters, EF, 2001) |
| "We studied the effect of the addition of omeprazole (20 mg once a day) to treatment with pancreatin (Pancrease, Cilag, Herentals, Belgium), two or four capsules three times a day, on fecal fat excretion in a double-blind, crossover fashion in nine patients with cystic fibrosis having persistent steatorrhea while taking Pancrease, two capsules three times a day (mean fecal fat excretion, 22." | 9.07 | Omeprazole enhances the efficacy of pancreatin (pancrease) in cystic fibrosis. ( Bakker, W; Heijerman, HG; Lamers, CB, 1991) |
| "The incidence of gastroesophageal reflux disease (GERD) is higher in patients with cystic fibrosis (CF) than in the general population." | 7.01 | Effect of omeprazole on symptoms of gastroesophageal reflux disease in children with cystic fibrosis. A randomized, double-blind, placebo-controlled trial. ( Banaszkiewicz, A; Dziekiewicz, M; Lisowska, A; Mielus, M; Radzikowski, A; Sands, D; Walkowiak, J, 2021) |
| " The large variability limited our ability to test for a difference in fat absorption and has significant implication for the use of this test, considered the gold standard, for determining enzyme dosage adequacy." | 6.70 | Ranitidine and omeprazole as adjuvant therapy to pancrelipase to improve fat absorption in patients with cystic fibrosis. ( Bowser, E; Francisco, MP; Novak, DA; Sherman, JM; Theriaque, D; Wagner, MH, 2002) |
| "Omeprazole improves fat digestion and absorption in cystic fibrosis patients with residual faecal fat loss despite maximal pancreatic enzyme substitution." | 5.10 | Omeprazole, a proton pump inhibitor, improves residual steatorrhoea in cystic fibrosis patients treated with high dose pancreatic enzymes. ( De Boeck, K; Proesmans, M, 2003) |
| " In this prospective open study of 14 children with cystic fibrosis (CF), we evaluated the effect of 1 year adjuvant therapy with lansoprazole, a proton pump inhibitor (PPI), on growth, fecal fat loss, body composition and lung function." | 5.09 | Changes in pulmonary hyperinflation and bronchial hyperresponsiveness following treatment with lansoprazole in children with cystic fibrosis. ( Donckerwolcke, R; Forget, PP; Hendriks, JJ; Kester, AD; Wouters, EF, 2001) |
| "We studied the effect of the addition of omeprazole (20 mg once a day) to treatment with pancreatin (Pancrease, Cilag, Herentals, Belgium), two or four capsules three times a day, on fecal fat excretion in a double-blind, crossover fashion in nine patients with cystic fibrosis having persistent steatorrhea while taking Pancrease, two capsules three times a day (mean fecal fat excretion, 22." | 5.07 | Omeprazole enhances the efficacy of pancreatin (pancrease) in cystic fibrosis. ( Bakker, W; Heijerman, HG; Lamers, CB, 1991) |
| "The incidence of gastroesophageal reflux disease (GERD) is higher in patients with cystic fibrosis (CF) than in the general population." | 3.01 | Effect of omeprazole on symptoms of gastroesophageal reflux disease in children with cystic fibrosis. A randomized, double-blind, placebo-controlled trial. ( Banaszkiewicz, A; Dziekiewicz, M; Lisowska, A; Mielus, M; Radzikowski, A; Sands, D; Walkowiak, J, 2021) |
| " The large variability limited our ability to test for a difference in fat absorption and has significant implication for the use of this test, considered the gold standard, for determining enzyme dosage adequacy." | 2.70 | Ranitidine and omeprazole as adjuvant therapy to pancrelipase to improve fat absorption in patients with cystic fibrosis. ( Bowser, E; Francisco, MP; Novak, DA; Sherman, JM; Theriaque, D; Wagner, MH, 2002) |
| "Pancreatic insufficiency is the second most important pathophysiological expression of cystic fibrosis (CF) and occurs in the majority of patients." | 2.38 | New modalities in the treatment of exocrine pancreatic insufficiency in cystic fibrosis. ( Heijerman, HG, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (37.50) | 18.2507 |
| 2000's | 7 (43.75) | 29.6817 |
| 2010's | 2 (12.50) | 24.3611 |
| 2020's | 1 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Chung, WJ | 1 |
| Goeckeler-Fried, JL | 1 |
| Havasi, V | 1 |
| Chiang, A | 1 |
| Rowe, SM | 1 |
| Plyler, ZE | 1 |
| Hong, JS | 1 |
| Mazur, M | 1 |
| Piazza, GA | 1 |
| Keeton, AB | 1 |
| White, EL | 1 |
| Rasmussen, L | 1 |
| Weissman, AM | 1 |
| Denny, RA | 1 |
| Brodsky, JL | 1 |
| Sorscher, EJ | 1 |
| Dziekiewicz, M | 1 |
| Mielus, M | 1 |
| Lisowska, A | 1 |
| Walkowiak, J | 1 |
| Sands, D | 1 |
| Radzikowski, A | 1 |
| Banaszkiewicz, A | 1 |
| Andrade, PHS | 1 |
| Lobo, IMF | 1 |
| da Silva, WB | 1 |
| Francisco, MP | 1 |
| Wagner, MH | 1 |
| Sherman, JM | 1 |
| Theriaque, D | 1 |
| Bowser, E | 1 |
| Novak, DA | 1 |
| Proesmans, M | 1 |
| De Boeck, K | 1 |
| Kaur, S | 1 |
| Norkina, O | 1 |
| Ziemer, D | 1 |
| Samuelson, LC | 1 |
| De Lisle, RC | 1 |
| Gan, KH | 1 |
| Heijerman, HG | 4 |
| Geus, WP | 1 |
| Bakker, W | 3 |
| Lamers, CB | 3 |
| Dijkman, JH | 1 |
| Barraclough, M | 1 |
| Taylor, CJ | 1 |
| Tran, TM | 1 |
| Van den Neucker, A | 1 |
| Hendriks, JJ | 2 |
| Forget, P | 1 |
| Forget, PP | 4 |
| Kester, AD | 1 |
| Donckerwolcke, R | 1 |
| Wouters, EF | 1 |
| Cuppoletti, J | 1 |
| Tewari, KP | 1 |
| Sherry, AM | 1 |
| Kupert, EY | 1 |
| Malinowska, DH | 1 |
| Hendriks, HJ | 2 |
| van Kreel, B | 1 |
| ter Heide, H | 1 |
| Heijmans, H | 1 |
| Menheere, PP | 1 |
| Spaapen, LJ | 1 |
| Bakker, JA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Proton Pump Inhibitors (PPI) and Fat Absorption in Subjects With Cystic Fibrosis (CF) and Exocrine Pancreatic Insufficiency (EPI)[NCT03551691] | Phase 2 | 19 participants (Actual) | Interventional | 2018-08-07 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for omeprazole and Cystic Fibrosis of Pancreas
| Article | Year |
|---|---|
New modalities in the treatment of exocrine pancreatic insufficiency in cystic fibrosis.
Topics: Cystic Fibrosis; Drug Therapy, Combination; Exocrine Pancreatic Insufficiency; Humans; Omeprazole; P | 1992 |
7 trials available for omeprazole and Cystic Fibrosis of Pancreas
| Article | Year |
|---|---|
Effect of omeprazole on symptoms of gastroesophageal reflux disease in children with cystic fibrosis. A randomized, double-blind, placebo-controlled trial.
Topics: Adolescent; Child; Child, Preschool; Cystic Fibrosis; Double-Blind Method; Gastroesophageal Reflux; | 2021 |
Ranitidine and omeprazole as adjuvant therapy to pancrelipase to improve fat absorption in patients with cystic fibrosis.
Topics: Adolescent; Adult; Child; Cross-Over Studies; Cystic Fibrosis; Dietary Fats; Double-Blind Method; Fe | 2002 |
Omeprazole, a proton pump inhibitor, improves residual steatorrhoea in cystic fibrosis patients treated with high dose pancreatic enzymes.
Topics: Adolescent; Child; Child, Preschool; Cross-Over Studies; Cystic Fibrosis; Dose-Response Relationship | 2003 |
Comparison of a high lipase pancreatic enzyme extract with a regular pancreatin preparation in adult cystic fibrosis patients.
Topics: Adult; Cystic Fibrosis; Feces; Female; Humans; Lipase; Lipid Metabolism; Male; Middle Aged; Nitrogen | 1994 |
Improvement of fecal fat excretion after addition of omeprazole to pancrease in cystic fibrosis is related to residual exocrine function of the pancreas.
Topics: Adult; Cystic Fibrosis; Double-Blind Method; Feces; Female; Humans; Lipid Metabolism; Male; Omeprazo | 1993 |
Changes in pulmonary hyperinflation and bronchial hyperresponsiveness following treatment with lansoprazole in children with cystic fibrosis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adipose Tissue; Adolescent; Body Composition; Body Height; | 2001 |
Omeprazole enhances the efficacy of pancreatin (pancrease) in cystic fibrosis.
Topics: Adult; Capsules; Celiac Disease; Cystic Fibrosis; Double-Blind Method; Drug Interactions; Drug Thera | 1991 |
8 other studies available for omeprazole and Cystic Fibrosis of Pancreas
| Article | Year |
|---|---|
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
Topics: Alleles; Benzoates; Cells, Cultured; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regu | 2016 |
Risk factors for adverse drug reactions in pediatric inpatients: A cohort study.
Topics: Adolescent; Adverse Drug Reaction Reporting Systems; Anesthesia, General; Anti-Bacterial Agents; Ant | 2017 |
Acidic duodenal pH alters gene expression in the cystic fibrosis mouse pancreas.
Topics: Acids; Amylases; Animals; Chimera; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regula | 2004 |
Twenty-four hour ambulatory gastric and duodenal pH profiles in cystic fibrosis: effect of duodenal hyperacidity on pancreatic enzyme function and fat absorption.
Topics: Absorption; Acids; Child; Child, Preschool; Circadian Rhythm; Cystic Fibrosis; Dietary Fats; Duodenu | 1996 |
Effects of a proton-pump inhibitor in cystic fibrosis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Anthropometry; Celiac Disease; Child; Ch | 1998 |
ClC-2 Cl- channels in human lung epithelia: activation by arachidonic acid, amidation, and acid-activated omeprazole.
Topics: 1-Methyl-3-isobutylxanthine; Adenosine Triphosphate; Amides; Arachidonic Acids; Cell Line; Cells, Cu | 2001 |
Effects of therapy with lansoprazole on intestinal permeability and inflammation in young cystic fibrosis patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Anti-Infective Agents; Biomarkers; Child; Child | 2001 |
Are children with cystic fibrosis who are treated with a proton-pump inhibitor at risk for vitamin B(12) deficiency?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Case-Control Studies; Child; Child, Preschool; | 2001 |